JRCT ID: jRCT2080223072
Registered date:12/01/2016
Basic Information
Recruitment status | |
---|---|
Health condition(s) or Problem(s) studied | Type 2 Diabetes Mellitus |
Date of first enrollment | 12/01/2016 |
Target sample size | 20 |
Countries of recruitment | |
Study type | Interventional |
Intervention(s) | investigational material(s) Generic name etc : DS-8500a INN of investigational material : Therapeutic category code : 396 Antidiabetic agents Dosage and Administration for Investigational material : Oral |
Outcome(s)
Primary Outcome | -First-phase secretion (Insulin and C-peptide) -Second-phase secretion (Insulin and C-peptide) |
---|---|
Secondary Outcome | -M value -M/I value -Disposition Index |
Key inclusion & exclusion criteria
Age minimum | >= 20age old |
---|---|
Age maximum | Not applicable |
Gender | Both |
Include criteria | Main Inclusion Criteria; 1)Patients aged >= 20 years 2)Japanese patients with type 2 diabetes mellitus 3)Patients who have >= 7.0% and < 9.0% HbA1c |
Exclude criteria | Main Exclusion Criteria; -Patients with type 1 diabetes mellitus or with a history of diabetic coma, precoma, or ketoacidosis -Patients receiving or requiring treatment with insulin -Patients with a body mass index (BMI) of < 18.5 kg/m2 or >= 35.0 kg/m2 -Patients with clinically evident renal impairment (estimated glomerular filtration rate [eGFR] of < 45 mL/min per 1.73 m2) or clinically significant renal disease -Patients with fasting plasma glucose >= 240 mg/dL |
Related Information
Primary Sponsor | DAIICHI SANKYO CO., LTD. |
---|---|
Secondary Sponsor | |
Source(s) of Monetary Support | |
Secondary ID(s) | JapicCTI-163126 |
Contact
Public contact | |
Name | |
Address | http://www.daiichisankyo.co.jp/corporate/rd/measure/clinical/index.html |
Telephone | |
Affiliation | DAIICHI SANKYO Co.,Ltd. |
Scientific contact | |
Name | |
Address | |
Telephone | |
Affiliation |